Human chorionic gonadotropin and luteinizing hormone-releasing hormone reverse the blockade of ovulation in pregnant mare's serum gonadotropin-primed immature rats by the anti-androgenic drug, hydroxyflutamide.
The present study was designed to examine mechanism(s) of the anti-ovulatory action of the anti-androgen, hydroxyflutamide (OH-F). Prepubertal rats were treated with 4 IU pregnant mare's serum gonadotropin (PMSG) (day -2) to induce first estrus and ovulation. They received OH-F in sesame oil or oil alone at 08:00 and 20:00 h on day 0 (the day of proestrus) and ovulations were assessed on the morning of day 1. Eighty-three percent of control animals ovulated with a mean of 7.7 +/- 1.1 corpora lutea per rat. Hydroxyflutamide blocked ovulation in all but 2 of the 12 rats receiving this drug alone. All of OH-F treated rats that received 5 and 25 IU human chorionic gonadotropin (hCG) ovulated with means +/- SEM of 9.1 +/- 0.1 and 7.3 +/- 1.4 corpora lutea per rat, respectively. The dose of 0.2 IU hCG was essentially ineffective, while the effect of 1.0 IU hCG was intermediate. At the dose of 20 ng and above (100 and 500 ng) luteining hormone-releasing hormone (LHRH) completely overcame the ovulation blockade in the OH-F treated animals, while a 4-ng dose was ineffective. At 18:00 h on the day of proestrus, serum LH levels in control animals were 17.56 +/- 2.60 ng/mL, which were 920% above basal levels (1.90 +/- 0.13) indicating a spontaneous LH surge. This surge was suppressed in OH-F treated rats. Injection of LHRH, at the dose of 20 ng and above, reinstated the LH release in OH-F treated animals. Thus, the anti-androgen, OH-F, inhibits ovulation in PMSG-treated immature rats through its interference with the preovulatory LH surge; the inhibition can be reversed by hCG or LHRH. Hydroxyflutamide does not appear to interfere at the level of the pituitary, but may have direct action at the hypothalamic and (or) extrahypothalamic sites involved in the generation of positive feedback signals that control LH release.
D000813:Anilides / Q000494:pharmacology*; D000818:Animals; D001826:Body Fluids / Q000502:physiology; D006063:Chorionic Gonadotropin / Q000502:physiology*; D005260:Female; D005485:Flutamide / Q000031:analogs & derivatives / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000502:physiology*; D006064:Gonadotropins, Equine / Q000494:pharmacology*; D006801:Humans; D009929:Organ Size; D010053:Ovary / Q000502:physiology; D010060:Ovulation / Q000187:drug effects*; D010902:Pituitary Gland / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains
D000813:Anilides; D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; C014290:hydroxyflutamide; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide